Abbott claims AVEIR DR is the world's first dual chamber leadless pacing system, which is designed to treat people with ...

Nick Flower, 79, underwent a groundbreaking procedure in March 2022, as part of a clinical trial for a new dual-chamber, ...

Abbott (NYSE: ABT) is reportedly kicking off the rollout of its Aveir DR leadless pacemaker system in the United Kingdom.

AUGUSTA, Ga. (WJBF) – Piedmont Augusta and Piedmont Heart Institute announced their electrophysiology team was the first in ...

The FDA approved Abbott's Aveir system, the first dual-chamber pacemaker approved by the agency, in July 2023. Dual-chamber pacemakers regulate contractions in the right ventricle and right atrium ...

A major highlight is the launch of the AVEIR™ DR dual-chamber leadless pacemaker in Canada, which is set to enhance Abbott Laboratories (NYSE:ABT)’s position in the cardiac care market.

Key product approvals include the Esprit™ BTK system, Lingo™ and Libre Rio™ glucose monitoring systems, and the AVEIR dual chamber leadless pacemaker. As of Q2 2024, there were 69 hedge fund ...